Key result
Adult hypertensive eNOS-/- mice had 15% lower arteriolar density compared to controls (P<0.05), and hydralazine treatment prevented both hypertension and arteriolar rarefaction.
Why the study?
Does hydralazine prevent arteriolar rarefaction and hypertension in eNOS-/- mice?
Population
8- and 12-week-old endothelial nitric oxide synthase knockout mice and C57BL6J littermates
Comparison
Hydralazine for 1 month vs Untreated eNOS-/- mice and eNOS+/+ control mice
Design
Preclinical
Follow-up
1 month
Authors
Loading...
May support angiogenesis research in hypertension models; leaves open any clinical relevance in humans.
Does hydralazine prevent arteriolar rarefaction and hypertension in eNOS-/- mice?
Effect estimate: 15% lower
p-value: p=< 0.05
Arteriolar rarefaction in eNOS-/- mice is driven by hypertension rather than the constitutive lack of eNOS, as it is prevented by the non-NO-dependent vasodilator hydralazine.
Kubis et al. (2002) studied Hypertension. Hydralazine vs. Untreated eNOS-/- mice and eNOS+/+ controls was evaluated on Arteriolar density in skeletal muscle and heart (15% lower, p=< 0.05). Adult hypertensive eNOS-/- mice had 15% lower arteriolar density compared to controls (P<0.05), and hydralazine treatment prevented both hypertension and arteriolar rarefaction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: